医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

RxAdvance Expands Executive Management Team

2013年10月10日 PM09:55
このエントリーをはてなブックマークに追加


 

SOUTHBOROUGH, Mass.

RxAdvance, an innovative pharmacy benefit management (PBM) company, has expanded its executive management team with another industry veteran, Anand Tati, who joins as executive vice president, operations and client engagement.

Anand Tati, executive vice president, operations and client engagement, is responsible for overall operations of the company including engaging prospective clients and building sustainable trusted client relationships. In addition, he will lead the onboarding of new clients and be responsible for defining the RxAdvance platform scope, developing functional module roadmaps and process blueprints, and executing and delivering complete client pharmacy benefit management solutions.

Tati brings over 20 years of experience in successful client implementation, business process re-engineering, and engagement. Prior to joining RxAdvance, Tati was a senior manager and on the partner track at Deloitte Consulting. While at Deloitte and as part of the Information Management practice, Tati provided strategic technology advisory and implementation services to commercial, federal, and state government clients such as the Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services (CMS), Housing and Urban Development (HUD), Time Warner, and Walmart. Prior to Deloitte, Tati was a product manager at IMS Health and Millennium Pharmaceuticals, and was a senior consultant at PricewaterhouseCoopers. He began his career at Infosys as a software engineer.

“The PBM industry is known for ‘business as usual’ and has been challenged to bring real value to plan sponsors (health plans, ACO’s, FFS government programs, self-funded groups) in addition to traditional transaction management. The PBM space is filled with multiple, fragmented, inflexible, and homegrown legacy systems that are expensive to operate, and hence unable to provide desired outcomes at the point of care and point of sale,” says Ravi Ika, Founder and CEO of RxAdvance. Ika adds, “Healthcare reform adds additional pressure on the plan sponsor’s PBM to demonstrate effective prescription benefit management through reduced adverse drug effects, better medication therapy management, comprehensive medication review, improved prescription adherence, reduced fraud and abuse, increased usage of generics, optimal usage of specialty medications including switching to low cost specialty drugs, and improving pharmacy related Star Ratings. Such value-added services require us to think outside the box and achieve the highest degree of sophistication within RxAdvance to deliver actionable information at the point of care and point of sale.” Ika says, “Anand brings such experience in business process re-engineering, thinking outside the box, and a game changing approach in implementation solutions.”

Tati has a bachelor of science degree in electrical engineering from the National Institute of Technology, India, and a masters in technology management from Penn Engineering and the Wharton School.

About RxAdvance

RxAdvance is a pharmacy benefit management (PBM) company created specifically for the future of healthcare. We are a single resource to help you better understand and manage standard formulary and specialty pharmaceutical and biologics usage. We bring together member, provider, and payer pharmacy case/care management staff with our own pharmacy and case/care management staff to facilitate the type of information sharing and decision-making that ultimately yields the best clinical and financial outcomes. Our tailored, world-class services for all plan sponsors — health plans, accountable care organizations (ACOs), state Medicaid programs, employer groups and unions — blend state-of-the-art technologies with experienced and talented professional teams to optimize your return on investment while enhancing your competitive stance in the market. For more information, visit www.rxadvance.com.

CONTACT

RxAdvance
Pooja Sammeta, 508-804-6900
pooja.sammeta@rxadvance.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表